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1. Introduction
Insulin is a hormone secreted from the β cells of the islets of Langerhans, specific groups of
cells in the pancreas. Insulin is a protein consisting of two polypeptide chains, one of 21 amino
acid residues and the other of 30, joined by two disulfide bridges. It was isolated in 1921 with
its first clinical use in 1922 [1]. Insulin is prepared different techniques; One of these isolated
from animals and the other is biotechnological preparation using with the recombinant DNA
techniques [2, 3].
Insulin is a important player in the control of intermediary metabolism and profound effects
on both carbohydrate and lipid metabolism. It has significant influence on protein and mineral
metabolism [4, 5].
The traditional and most predictable method for the administration of insulin is by subcuta‐
neous injections. This method is often painful and hence, deterrent to patient compliance
especially for those requiring multiple dose injections of four times a day. Also, there have
been reports of hypoglycemic episodes following multi dose injections of insulin [6, 7]. Several
new approaches to the method have been adopted to decrease the suffering of the diabetic
patients including the use of supersonic injector, infusion pump, sharp needles and pens. Some
insulin delivery routs so problematic way for example oral administration; Oral delivery
eliminates the pain caused by injection, psychological barriers associated with multiple daily
injections. Oral delivery of insulin as a non-invasive therapy for Diabetes Mellitus is still a
challenge to the drug delivery technology, because insulin is degraded by the enzymes in the
acidic environment of stomach. Otherwise insulin delivery via transdermal delivery is so
popular way of insulin administration but there are some disadvantages of this route, for
example insulin molecular size and application problems etc. While some of them eased the
pain encountered by the diabetic patients, they offer incomplete convenience. Even though
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the ultimate goal would be to eliminate the need to deliver insulin exogenously and regaining
the ability of patients to produce and use own insulin, new concepts are currently explored to
deliver insulin using oral, pulmonary, nasal, ocular and rectal routes [8, 9].
The success of the route of administration is judged on the basis of its ability to elicit effective
and predictable lowering of blood glucose level and therefore minimizing the risk of diabetic
complications. It is clear that several difficulties have to overcome with the use of formulation
and application devices technology [10, 11]. The various explored routes are reviewed in this
chapter. On the other hand, the chapter is an attempt to illustrate the use of insulin drug
delivery and their body route in diabetes management benefiting many diabetic patients with
promising patient compliance.
Diabetes mellitus (DM) which is a metabolic disorder characterized by chronic hyperglycemia
(increased blood and hepatic glucose levels) with disturbances in carbohydrate, fat and protein
metabolism, resulted by diminished insulin secretion, impaired insulin action or both. It’s
expected to increase from 171 million in 2000 to 366 million by the year 2030 as predicted by
the WHO so it continues to increase in prevalence and will become a serious threat of mankind
health [12]. Insulin injections remain to be preferred approach for the treatment of insulin-
dependent diabetes mellitus (T1DM) and for many patients non-insulin-dependent diabetes
mellitus (T2DM) also. People with type 1 diabetes mellitus have an autoimmun mediated
destruction of pancreatic islet beta-cells and insulin deficiency. T1DM usually occurs in
children and young adults and require daily insulin administration by injection or an insulin
pump for survival. On the other hand, insulin resistance (which is associated with excessive
glucose production by the liver and impaired glucose utilization by peripheral tissue, espe‐
cially muscle) is observed in T2DM. They have an impaired endogenous insulin secretion to
deal with the increased blood glucose level and majority needs oral antidiabetic drugs. As the
disease progresses, the pancreas looses its ability to produce insulin and necessity of insulin
therapy increases [12, 13, 14].
Hyperglycemia, recurrence of ample fluctuation of blood glucose levels and insulin resistance
can lead to long term complications such as micro and macrovascular. It is well known that
improved metabolic control significantly reduces both microvascular (ie, retinopathy, nephr‐
opathy and neuropathy) or macrovascular [ie, cardiovascular disease (CVD), cerebrovascular
accidents and peripheral vascular disease] complications in diabetes. The development of
complications is a cause of considerable morbidity and increases disability and mortality for
the individual with diabetes [15].
The conventional pharmacotherapies currently available for the treatment of type-2 diabetes
include insulin sensitisers (metformin and thiazolidinediones), insulin secretagogues (sulpho‐
nylureas and glinides), alpha-glucosidase inhibitors, insulin and insulin analogues. Glucagon
like peptide (GLP)-1 agonists and dipeptidyl peptidase (DPP)-4 inhibitors are the new
therapies; that improve glycemic control have recently been developed [16, 17, 18, 19]. These
therapies are proposed to treat the key metabolic abnormalities associated with T1DM and
T2DM and minimize the side effects noted with conventional therapies. Also in development
there are additional therapies that have effects on the kidney to promote glucose excretion [15].
SGLT-2 (proximal renal tubule) has high transport capacity for reabsorption of approximately
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90% of primarily filtered glucose. SGLT-2 inhibitors inhibit glucose reabsorption in proximal
renal tubule. It results glycosuria leads to a decline in plasma glucose level. A wide variety of
SGLT-2 inhibitors are currently under development with Dapagliflozin, Canagliflozin,
Empagliflozin being the most advanced substances. Excretion of approximately 40% of
primarily filtered glucose translates to a loss of 50–100 g glucose every day. The consequential
decline in fasting and postprandial glucose leads to an HbA1c reduction of approximately
0.8%. The loss of energy substrate reduces body weight approximately 3 kg.
Current therapy for diabetes mellitus through oral anti-diabetic drugs and subcutaneous
administration of insulin suffers from serious disadvantages, such as patient noncompliance
and occasional hypoglycemia. Moreover, these approaches don’t mimic the normal physio‐
logical fate of insulin release and doesn’t provide better glucose homeostasis. In normal human
physiology when the blood glucose level increases insulin releases from the pancreas, reaches
to the hepatic portal vein and goes to liver which is its primary site of action. Subcutaneous
administration of insulin moves firstly peripheral tissues and can produce peripheric hyper‐
insulinemia. In order to overcome the problems associated with parenteral administration of
insulin, substantial progress has been made for insulin route such as ocular, vaginal, rectal,
oral, pulmonary, transdermal, intranasal, and other routes (Figure 1) [20]. The barriers to
reaching the bloodstream are either physical, such as poor absorption at barrier surfaces, or
chemical, such as pH inactivation and enzymatic degradation. Delivery of insulin via the
ocular route was tested in animal models in combination with different absorption enhancers,
with particular attention given to toxicity as polymers were added to overcome low absorption.
Vaginal and rectal routes of insulin have also been evaluated but the absorption rate and
bioavailability are poor due to the thick mucosal layers in these tissues. Lots of absorption
enhancers (bile salts, chelating agents, surfactants, cyclodextrins, and dihydrofusidate) used
but they couldn’t prevent local reactions with severe complications.
Figure 1. The main administration routes for insulin delivery (Reproduced with permission from Ref. [20], Copyright
2013 Elsevier)
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Nasal delivery has also been evaluated because of the easy access, high vascularity and large
absorption area associated with this route. Unfortunately, highly active mucociliary clearance
in the nose hindered prolonged drug action resulting in poor bioavailability. Buccal and
sublingual insulin administration provide better results due to the low levels of proteolytic
enzyme activity, the high vascularization of the tissue, the large surface area for absorption
and the ease of administration. Unlike other delivery routes, the gut is the natural route of
nutrient absorption into the circulation. The fact that the gut presents the largest absorption
surface of all routes provides better efficacy. However, the multiple layers of oral epithelial
cells represent a significant GI barrier to drug penetration, which, coupled with the continuous
flow of saliva, leads to poor efficacy.
Taking all of this account oral administration is considered to be the most safest and convenient
which delivers the drug directly into the liver through portal circulation, where it inhibits
hepatic glucose production. Hence by oral delivery to a greater extent the natural physiological
route of insulin can be mimicked (Figure 2) [21]. The highly acidic environment in the stomach
and the presence of proteolytic enzymes cause structural instability of the oral delivery of
protein and peptide drugs including in the harsh environment of the gastrointestinal system
[22, 23, 24]. These drugs should overcome some various GI barriers such as chemical, enzy‐
matic and absorption barriers to obtain adequate bioavailability [25]. Different formulation of
polymers for insulin delivery such as liposomes, microspheres, microemulsion and nanopar‐
ticles (NPs) have been investigated to circumvent these GI barriers [26, 27].
Figure 2. Schematic diagrams illustrating the absorption, distribution and elimination of aspart insulin following oral
or subcutaneous (s.c.) administration to rats (Reproduced with permission from Ref. [21], Copyright 2013 Elsevier).
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Among these approaches nanoparticular sysytems have attracted special interest because of
providing the protection to the highly acidic medium in the stomach (preventing enzymatic
degradation), prolonging intestinal residence time, increasing the permeability of drugs to
systemic circulation (increasing absorption) and providing controlled-release properties for
encapsulated drug [12, 28]. For the conventional medicine it is well understood the nanosize
along with other characteristics does play an important role as evident from the improved
bioavailability/pharmacological availability [29, 30]. Owing to the high surface area to volume
ratio of NPs the window of absorption is also high in comparison with microparticles, this is
an added advantage in improving the bioavailability of the administered drug [31, 32].
2. Delivery route of insulin
2.1. Oral delivery
Insulin therapy is effectively used in treatment of diabetes mellitus. Insulin is a key player in
lowering blood glucose levels for type 1 diabetes and also required at later stages in type 2
diabetes patients. The widely accepted route for delivery of insulin is by parenteral adminis‐
tration but this delivery of insulin usually requires at least three or four daily insulin injections
for good glycemic control. Consequently more acceptable different routes of insulin delivery
have been searched to decrease suffering from discomfort, local pain, irritation, infection,
immune reactions and lipoatrophy at the injection site of insulin. Oral delivery of insulin would
deliver the drug directly into the liver through portal circulation and could mimic the phys‐
iological fate of endogenously secreted insulin [33, 34, 35]. However polypeptides, like insulin
are degraded in the stomach pH and undergo proteolysis by enzymes in the gastrointestinal
tract [22, 36]. Moreover the gastrointestinal mucosa has low permeability for large hydrophilic
peptides.
In order to overcome the problems associated with parenteral administration of insulin several
strategies that are based on nanotechnology has been developed to enhance the intestinal
absorption of different protein and peptides. NPs consist of naturally occurring biodegradable
polymers are widely investigated in this regard. They have emerged as potential carriers of
several therapeutic agents for controlled drug delivery as well as the oral route of insulin.
Various natural hydrophilic and hydrophobic polymers used as carrier of oral insulin such as
chitosan, alginate, dextran sulphate, etc. are commonly used to prepare NPs.
2.1.1. Polymers used as matrices for oral insulin delivery
Over the past few decades, enhancing attention has been paid to the use of polymeric NPs
either hydrophilic or hydrophobic as carriers for insulin delivery. Hydrophilic polymers are
of particular interest due to their non-toxic, biocompatible, biodegradable and natural
polymers. Among them, chitosan is widely used because of its ease of chemical modification
and promising biological properties.
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2.1.1.1. Hydrophilic polymers
Chitosan (CS): CS is well known naturally occuring copolymer of beta [1-4] linked and N-acetyl
glucosamine and have been generally found in crustacean (crabs, shrimps and lobsters) shell
and in some fungi or yeast. It is a biodegradable, biocompatible, non toxic, non-allergic easily
absorbable natural hydrophilic polymer properties that have resulted in a wide array of
applications in biomedical and drug delivery research [29, 30, 37]. Moreover it prolongs the
intestinal residence time that shows its mucoadhesive property [38] (Figure 3). It has also been
shown as a paracellular permeability enhancer by interacting with the TJ proteins occluding
ZO-1 and opens the tight junctions between epithelial cells [34, 39, 40]. In addition to these
properties it increases the stability of nanospheres and faciliates effective encapsulation of
proteins and drugs that make it as a suitable carrier material [38, 41, 42]. CS have been
extensively used to develope new chitosan derivatized polymers. CS combined with poly(γ-
glutamic acid) (γ-PGA) based insulin NPs are used as hydrophilic polymers for oral insulin
delivery. In vivo preclinical studies of this formulations at a dose of 30 IU/kg in streptozotocin
(STZ) induced diabetic rat models showed increased intestinal absorption of insulin from γ-
PGA NPs. It has got long lasting hypoglycemic effect and 15% relative bioavailability com‐
pared to subcutaneous (sc) injection [43]. The same formulation filled in enteric coated capsules
was even better at the same dose, showing 20% oral bioavailability. Also aspart insulin
(=monomeric, 3 times faster than regular) is encapsulated in the same CS-γ-PGA; has got 15.7
% oral bioavailability [21, 44].
Moreover insulin loaded NPs with carboxylated chitosan and Poly-methyl methacrylate
(PMMA) were developed to improve the insulin delivery via oral route. One of the most widely
investigated polymer towards peptide delivery is acrylates which have high interest because
of its pH sensitivity and carboxyl groups to enhance the bioadhesivity, alter the tight junction,
chelate the Ca2+ there by inhibiting the proteolytic activity of proteases, etc. They evaluated
their ability to reduce blood glucose levels in diabetic rats. In vivo experiments resulted in the
reduction of blood glucose levels by 67% at a dose of 100 IU/kg and the pharmacological
bioavailability of the 25 IU/kg at a dose of PMMA NPs was 9.7% [45, 46].
Chitosan with sodium alginate is being prepared another insulin loaded nanoparticle product
which is used to improve the loading capacity and activity maintenance. It’s observed that
when insulin-loaded nanospheres (25, 50, 100 IU/kg) administered orally to diabetic rats they
reduced glycaemia in a dose dependent manner. Their pharmacological availabilities are
found 7.1, 6.8 and 3.4 %, respectively [33, 47, 48].
In addition hydroxypropyl methylcellulose phthalate (HPMCP) is a pH-sensitive polymer
designed as an enteric coating material. It reduces the release of drug in acidic conditions and
also to improve the colloidal stability of the particles. The release of insulin from CS/HPMCP
NPs were significantly reduced at acidic pH and even after 6 h it was less about 25% only.
Insulin was protected from enzymatic degradation in the case of CS/HPMCP in comparison
with native chitosan particles. Insulin loaded chitosan and HPMCP NPs were orally admin‐
istered to diabetic wistar rats. The pharmacological availability was 3.02% and 8.47%, respec‐
tively, for the chitosan and the modified NPs. In comparison to oral insulin solution the
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hypoglycaemic effect was increased by 2.8 and 9.8-folds for the chitosan and the modified NPs,
respectively [49, 50, 51].
Dextran sulphate-vitamin B12: Dextran sulphate is a non-toxic and highly water soluble different
polymer used as matrices for oral delivery of insulin. Vitamin-B12 demonstrated as a ligand to
enhance the uptake of the dextran NPs and their translocation across the gastrointestinal tract
for high bioavailability. Insulin conjugated to dextran-vitamin B12 NPs to diabetic rats that had
the least amount of cross linking were found to be most effective at lowering blood glucose
levels (70-75%) in STZ induced diabetic rats. In addition the hypoglycemic effect lasted for 54
h. This modification showed the greatest hypoglycemic effect with a pharmacological availa‐
bility of 29.4% (Table 1) [49, 52, 53].
2.1.1.2. Hydrophobic polymers
Poly (lactide-co-glycolide) (PLGA): Particles consisting of PLGA have been widely studied as
therapeutic delivery vehicles owing to their biodegradabile and biocompatibile particles. The
hydrophobic nature of PLGA matrices generally makes them incapable of entrapping water-
soluble insulin. Intragastric administration of the insulin-loaded PLGA NPs (20 IU/kg) to
diabetic rats reduced fasting plasma glucose levels to 57.4% within the first 8h of administra‐
tion. The relative bioavailability of insulin following oral administration of NPs was 7.7%
compared to subcutaneous injection of its solution. Star-branched PLGA (β-cyclodextrin-
PLGA) NPs are highly promising for mitigating the burst effect and prolonging the release of
insulin. Another study attempted to prevent the burst release of insulin in the stomach by
Figure 3. In-vivo efficiency of orally delivered insulin and chitosan/insulin self-assembled NPs (Reproduced with per‐
mission from Ref. [38], Copyright 2013 Elsevier).
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using a cellulose derivative (hydroxypropyl methylcellulose phthalate, HPMCP) to prepare
PLGA NPs. This modification reduced the initial release of PLGA NPs in simulated gastric
fluid from 50% to 20%, and their relative bioavailability in diabetic rats was approximately
6.2% [49, 58, 59].
Poly lactide acide (PLA): PLA exhibit a strong affinity toward the small intestine due to their
polyethylene oxide (PEO) blocks and a high permeation capability toward the cell membrane
owing to their amphiphilic property. When orally treated with vesicular PLA NPs loaded with
insulin to diabetic mice (50 IU/kg), the highest blood glucose reduction was achieved at 4.5 h.
Although this effect lasted at least an additional 18.5 h, increasing the insulin concentration to
100 IU/kg did not enhance this hypoglycemic effect (hypoglycemic effect lasted for 23 hr)
[60].
Poly-ε-caprolactone (PCL): NPs prepared with PCL and a monomeric form of insulin analog
(aspart-insulin). Their results demonstrated that this formulation allows for preservation of
biological activities of insulin, increase of serum insulin levels and improvement of the
glycemic response. The maximum effect of reduction in hyperglycemia was found at 8 h after
oral administration, which was more pronounced with aspart-insulin-loaded NPs (52%) at the
dose of 50 IU/kg [61].
Lipidic polymers [Solid lipid NPs (SLN)]: Previous studies have demonstrated that nanoencap‐
sulation of proteins in SLNs prolongs their blood residence time, modifies their biodistribution
and improves their bioavailability [32]. Oral insulin delivery with SLNs administered to
diabetic rats, their relative pharmacological bioavailability was 5.1% in comparison to SC
injection of insulin; a considerable hypoglycemic effect was also observed during 24 h. To
facilitate the transport of particles across the cellular barriers, in an another study the relative
bioavailability increased to 7.1%. That study also suggested that increasing the drug entrap‐
Particle Size (nm) Dose (IU/kg) PharmacologicalActivity (PA %) Reference
CS-γPGA 218 30 15.1
21, 43, 44Entericcoated(EC) 233 30 20.1
Aspart Insulin 245 30 15.7
CS-PMMA-PEG 1000 50 1.8 45
CS-PMMA 200-300 25 9.7 46
CS-NP 25-400 7, 14, 21 14, 15.6, 15.3 54
CS-dextran sulfate 500 50, 100 5.6, 3.4 55
CS/HPMCP 255 12.5 8.47 56
CS-Na alginate 748 25, 50, 100 7.1, 6.8, 3.4 57
B12vitamin-dextran 192 20 29.4, 26.5 52, 53
Table 1. Hydrophilic Polymers.
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ment efficiency and utilizing protease inhibitors in SLNs may further enhance the bioavaila‐
bility of insulin (Table 2).
Particle Size (nm) Dose (IU/kg) BA (relativebioavailability)% Reference
PLGA 150 20 40 7.7 46
PLGA-HPMCP 169 20 60 6.27 59
PLA 50 Hypoglycemic effect lastedfor 23 h 60
PCL, Aspart insulin
loaded 700 50 52/ 12-24 hr 61
Table 2. Hydrophobic Polymers.
2.2. Nasal delivery
Nasal administration has attracted a lot of interest as a highly efficient route for the systemic
delivery of insulin. It has been well known that the pharmacokinetic profile of intranasal
insulin resembles the pulsatile pattern of endogenous insulin secretion in healthy volunteers
during meal times [62]. In addition it’s considered as a promising route for the following
reasons: the nose has relatively large surface area [150 cm2] of absorption because of numerous
microvilli, high vascularized subepithelial layer that passes directly into the systemic circula‐
tion, thereby avoiding the loss of drug by first pass metabolism in the liver, high permeability
of the nasal epithelial membrane and lower enzymatic activity than the gastrointestinal tract.
Although nasal administration of insulin has many advantages, there are also some barriers
that limit the intranasal absorption of insulin. Macociliary clearance of formulations from the
nasal cavity, low permeability of nasal mucosa to large molecules and the low bioavailability
of insulin act as barriers to intranasal absorption. To overcome the various barriers by the nasal
route, researchers have studied many extensive range of enhancers such as bile salts and
derivatives, sodium lauryl sulfate, laureth-9, phospholipids, cyclodextrins, chitosan and
enzyme inhibitors.
At first CS NPs is seemed to be the safest and most effective as a carrier for the nasal delivery
of insulin. It protected insulin from degradation in the nasal cavity and increased intranasal
absorption of insulin with its positive charge [20, 63]. Also PEG-grafted(g) have been used to
enhance the solubility and improve the biocompatibility of CS. Insulin PEG-g with CS NPs
administered intranasally to transport insulin across the nasal mucosa in rabbits [64]. However
recent studies showed that insulin-CS solution formulation was more effective than the
intranasal NP complex (Bioavailability 17 %, 3.6 % respectively) [65]. Because of NPs couldn’t
enhance the uptake of insulin; PEGylated trimethyl CS NP results was also not found signifi‐
cantly different from the insulin-CS solution formulation. Besides chitosan reduced gold NPs
could enhance insulin transport into cells effectively. After insulin loaded gold Nps adminis‐
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tered to diabetic rats by intranasally blood glucose concentration was decreased by 20.27 %
[66]. Moreover intranasal route of insulin loaded starch NPs containing sodium glycocholate
which’s used as mucoadhesive carrier, caused 70 % reduction of plasma glucose levels and
significant hypoglycemia untill 6h in the STZ induced diabetic rats [67].
2.3. Pulmonary delivery
Pulmonary administration is one of the most promising alternative route of insulin delivery.
The lungs offer a large and highly vascularised surface area for drug absorption approximately
80-140 m2. Alveoles are covered by a very thin (0.1-0.2 mm) monolayer epithelium, that permits
rapid drug absorption. The alveoli can be effectively targeted for drug absorption by drug
delivery as an aerosol with a mass median aerodynamic diameter of less than 5µm. First pass
metabolism in this administration avoids gastrointestinal system metabolism. Although
metabolic enzymes are found in the lungs, their activities and pathways may be different from
those found in the GIT and this makes the pulmonary route of many therapeutic proteins and
peptides very promising [68, 69, 70].
There are variety of inhalation devices such as metered-dose inhalers or drug powder inhalers.
Such as AERx®. Insulin Diabetes Management system developed by Novo Nordisk which
delivers aerosol of human insulin; Exubera® developed by Nektar/Pfizer which uses a dry
powder formulation. [36].
Dry powder inhalers are currently the most commonly used devices because of their stability
and sterility to develope pulmonary insulin. The surfactants, bile salts and fatty acids have
been evaluated as absorption enhancers which increase the permeability of drugs through the
epithelial membranes. However polyoxyethylene (PE) oleyl ether showed good enhancement
sorbitan trioleate exhibited moderate enhancing ability. The enhancing effects of glycerol
trioleate, ethyl oleate, oleyl alcohol, palmitic acid and stearic acid were very low. In contrast
liposomes are very effective pulmonary absorption enhancers for peptide and protein drugs.
They’ve biogenic phospholipids and biocompatible, biodegradable and non immunogenic
natural properties.
Experimental studies investigated that insulin could be efficiently encapsulated in liposomes
which has approximately 1µm particle size. Liposome mediated pulmonary drug causes
enhancement in drug retention time in the lungs and decreases side effects which results
increased therapeutic effects. When aerolized insulin liposomes delivered by the inhalation
route in mice caused significantly reduction in plasma glucose concentrations [71]. Insulin-
calcium phosphate (CAP) and polyethylene glycol (PEG) particles were administered to the
lungs by a route of administration of respiratory tract and these particles positively affected
the disposition of the insulin in the lungs of rats [72]. Poly-lactide-co-glycolide (PLGA) particles
have used to improve insulin loaded particles which has a mean diameter of 400 nm. After the
pulmonary administration of insulin with PLGA nanospheres, blood glucose levels were
significantly decreased and has got prolonged hypoglycemic response over 48 h in guinea pigs
[73]. In another related study poly butyl cyanoacrylate NPs have been used given by pulmo‐
nary inhalation of insulin in the lungs resulted stable and prolonged pharmacological effect.
A significant reduction in glucose levels were found and the relative pharmacological
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bioavailability was 57.2 % [70]. Besides insulin/1, 2 dipalmitoyl phosphatidylcholine (DPPC)
physical mixture used to enhance insulin absorption in pulmonary route of inhalation. This
mixture caused higher blood glucose decrease because of their potentially effective, non-toxic
and natural absorption enhancer property [74].
2.4. Buccal delivery
Insulin delivered by buccal route is through an aerosol spray into the oral cavity. It’s absorbed
through the inside of the cheeks and in the back of the mouth. The buccal mucosa is excellently
accessible with surface area approximately 100-200 cm2, lower risk to be traumatized and a
relatively good permeability and perfusion [36, 75, 76, 77]. Several formulations and factors
alone or in combination can influence release properties of buccal insulin delivery system.
These formulations should contain absorption enhancers (such as surfactants, bile salts,
chelators, sodium lauryl sulfate or fatty acids) to increase membrane permeability, enzyme
inhibitors to protect the drug from degradation, protease inhibitors (aprotinin and sodium
glycocholate) to function drug permeation across mucosa, lipophilicity modifications (conju‐
gation with polymers) bioadhesive delivery systems (gels, films, patchs) and liposomal
formulations [36, 76, 78]. Lysalbinic acid which is applied as an absorption enhancer was
shown to enhance significantly buccal mucosa permeability for insulin. They investigated that
it’s a product of the alkaline hydrolysis of egg albumin and has no irritating or sensibilizing
effect upon buccal use. Co-administration of lysalbinic acid and relatively small proteins such
as insulin can increase insulin’s permeability from the cheek mucosa of hamster [79].
In the last years a new innovative system has been developed by Generex Biotechnology
Corporation (Toronto, Canada). It’s based on a liquid formulation (Oral-Lyn®) of recombinant
human insulin, absorption enhancers (which encapsulate and protect the Insulin molecules)
and Rapid Mist® device (advanced buccal drug delivery technology). This device sends fastly
small particles from an aqueous spray into the oral cavity. This allows rapid insulin absorption.
Oral-Lyn®  has  been evaluated in  healthy persons and type I  diabetes.  It  appears  in  the
circulation within 10 min, the time to peak insulin concentration is is around 25 min. It has
observed a more fast onset of action and less prolonged hypoglycemic action. Several studies
in patients both type 1 and 2 diabetes demonstrated that this oral insulin can be efficient
in  controlling  postprandial  glucose  levels.  This  new buccal  insuin  system needs  further
investigations in diabetic patients [35, 36, 76, 78].
2.5. Transdermal delivery
Transdermal insulin delivery is an appealing alternative to the invasive parenteral route of
administration and other alternative routes of insulin such as pulmonary and nasal routes
because the skin offers the advantages of an easy access and a very large surface area (1-2
m2).  It  improves  patient  compliance  and  avoids  both  liver’s  first  pass  metabolism  and
degradation of drugs in gastrointestinal tract. The skin also represents an important painless
interface for systemic drug administration. Despite these advantages the human skin limits
permeation of foreign compounds especially large hydrophilic molecules like insulin. The
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stratum corneum; which is the upper layer causes impermeability of the skin by its lipid-
rich matrix. Several attemps have been made to overcome the skin barrier and to allow the
transfer of large drugs such as insulin. They can be divided into chemical (liposome and
chemical enhancers) and physical methods (mainly iontophoresis and sonophoresis).
2.5.1. Transdermal delivery methods
Chemical enhancers  such as surfactants, fatty acids, fatty esters and azone-like compounds
alter  the  lipid structure  of  the  stratum corneum. They reduce its  barrier  properties  and
enhance its permeability for large molecule drugs that would not pass through the skin.
Iontophoresis  is a non invasive technique used to increase transdermal insulin penetration
through  the  skin  by  the  application  of  a  small  electric  current  potential.  Large  drug
molecules can be delivered in a shorter time with the help of this method and it increas‐
es drug’s mobility.
Another non invasive technique sonophoresis (ultrasound, phonophoresis) which has been used
to enhance (and or or delivery and activity of drugs) skin permeability to various low and
high  molecules  weight  drugs  such  as  inulin.  Low  frequency  ultrasound  (20-160  kHz)
decreases blood glucose levels both in animal and human studies [36, 72, 75].
Microneedles  are  minimally invasive painless  and promising technology to  deliver  drugs
into  the  skin  without  disruption  of  nerve  endings.  This  technology  create  micronsized
channels  which  interstitial  fluid  fills  up  the  channels  in  the  skin.  It  makes  hydrophilic
transport pathway, faciliates the stratum corneum barrier and increases skin permeability
to large molecules [35, 36, 62, 75].
Also other methods have been investigated like microdermabrasion, pressure waves and
electroporation but they’re still in at a preliminary stage. Altogether chemical and physi‐
cal methods they all need further investigations.
2.6. Ocular delivery
Ocular delivery is another the most promising and challenging delivery of ophthalmologi‐
cally active peptides and proteins for the treatment of ocular diseases. The advantages of
the ocular delivery are;  less development of immunological reactions in eye tissues,  less
side  effects,  no  tolerance  and  avoidance  of  hepatic  first  pass  metabolism.  While  the
enhancers  such  as  saponin,  dodecylmaltoside,  tetradecylmaltoside,  fusidic  acid  and
glycocholate  increases  the  systemic  absorption  of  insulin  in  animals  they  may  also  in‐
crease the eye toxicity [36, 80, 81]. A series of alkylglycosides including tetradecyl-, tridecyl-
and dodecylmaltoside and dodecylsucrose were potent  stimulators of  insulin absorption
after  topical  ocular  delivery in anesthetized rats  when used at  concentrations as  low as
0.125  %.  These  are  the  most  hydrophobic  alkylglycoside  reagents  and  were  the  most
effective  at  enhancing  systemic  insulin  absorption  [82].  Moreover  sucrose  cocoate,  a
pharmacological  excipient  of  cosmetic  and dermatologic  preparation was used to  deter‐
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mine its  possible  absorption enhancer in ocular  drug delivery.  When insulin was deliv‐
ered  ocularly  in  the  presence  of  0.5  %  sucrose  cocoate,  plasma  insulin  levels  were
significantly  enhanced  and  blood  glucose  levels  were  reduced  [83].  Because  of  this
observation insulin-containing liposome was prepared to prolong the retention time of the
formulation in the precorneal area [84]. This positively charged formulation decreased the
blood glucose levels 65-70%.
More  recently  Gelfoam® an  absorbable  gelatin  sponge  ocular  devices  have  been  devel‐
oped  as  insulin  carriers  for  systemic  administration  of  insulin.  Although  Gelfoam®
containing 0.2 mg insulin has been showed prolonged systemic absorption of insulin within
the desired therapeutic levels it may also cause long term toxicity such as slowing the tear
production. Because of this toxicity sodium insulin and zinc insulin Gelfoam ocular devices
have been developed and these devices were sufficient to control blood glucose levels (60
% of initial) for over 8 hours [62].
2.7. Vaginal delivery
In recent years numerous studies prove that vagina has got rich blood supply and large
surface area that means good permeability and can be a potential route for systemic delivery
to  a  wide range of  compounds.  The main advantages  of  vaginal  drug route  are  avoid‐
ance  of  first  pass  metabolism,  ease  of  administration  and  good  permeability  for  low
molecular  weight  drugs.  For  systemic  delivery bile  salts,  dihydrofusidate,  cyclodextrins,
surfactants and chelating agents have been tested as enhancers to facilitate the rate of vaginal
absorption but sometimes they induced several local reactions [36, 75].
2.8. Rectal delivery
Rectal route of delivery have been tested soon after the discovery of insulin but several
investigators  have  met  absorption  problems  through  the  mucosa.  This  administration’s
promising advantage is the possibility of avoiding, to some extent,  the hepatic first-pass
metabolism. Absorption promoters and surfactants were used to provide highest hypogly‐
cemic  effect  in  rectal  insulin  delivery.  The  most  effective  rectal  absorption  enhancer
polyoxyethylene-9-lauryl ether (POELE) or sodium salicylate were used in insulin supposi‐
tories on diabetic dogs. It was investigated that hypoglycemic effect can be achieved about
50-55 % [85].
3. Conclusion
Over  the  last  years  numerous  studies  summerised  polymeric  NPs  focused  on  different
routes  of  insulin  delivery.  The  association of  insulin  with  NP formulations  designed to
protect  insulin  from  degradation  and  enhance  its  uptake  in  the  ileum.  However,  more
research in this area is needed to achieve the goal that has plagued researchers for many
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decades. At any rate, polymeric NPs for routes of insulin delivery seems to be the better
alternative compared to others.
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